Try a new search

Format these results:

Searched for:

person:heratr01

in-biosketch:true

Total Results:

57


SARS-CoV-2 inflammation durably imprints memory CD4 T cells

Gray-Gaillard, Sophie L; Solis, Sabrina M; Chen, Han M; Monteiro, Clarice; Ciabattoni, Grace; Samanovic, Marie I; Cornelius, Amber R; Williams, Tijaana; Geesey, Emilie; Rodriguez, Miguel; Ortigoza, Mila Brum; Ivanova, Ellie N; Koralov, Sergei B; Mulligan, Mark J; Herati, Ramin Sedaghat
Memory CD4 T cells are critical to human immunity, yet it is unclear whether viral inflammation during memory formation has long-term consequences. Here, we compared transcriptional and epigenetic landscapes of Spike (S)-specific memory CD4 T cells in 24 individuals whose first exposure to S was via SARS-CoV-2 infection or mRNA vaccination. Nearly 2 years after memory formation, S-specific CD4 T cells established by infection remained enriched for transcripts related to cytotoxicity and for interferon-stimulated genes, likely because of a chromatin accessibility landscape altered by inflammation. Moreover, S-specific CD4 T cells primed by infection had reduced proliferative capacity in vitro relative to vaccine-primed cells. Furthermore, the transcriptional state of S-specific memory CD4 T cells was minimally altered by booster immunization and/or breakthrough infection. Thus, infection-associated inflammation durably imprints CD4 T cell memory, which affects the function of these cells and may have consequences for long-term immunity.
PMID: 38905326
ISSN: 2470-9468
CID: 5672432

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Herati, Ramin Sedaghat; Knorr, David A; Vella, Laura A; Silva, Luisa Victoria; Chilukuri, Lakshmi; Apostolidis, Sokratis A; Huang, Alexander C; Muselman, Alexander; Manne, Sasikanth; Kuthuru, Oliva; Staupe, Ryan P; Adamski, Sharon A; Kannan, Senthil; Kurupati, Raj K; Ertl, Hildegund C J; Wong, Jeffrey L; Bournazos, Stylianos; McGettigan, Suzanne; Schuchter, Lynn M; Kotecha, Ritesh R; Funt, Samuel A; Voss, Martin H; Motzer, Robert J; Lee, Chung-Han; Bajorin, Dean F; Mitchell, Tara C; Ravetch, Jeffrey V; Wherry, E John
Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell responses in patients with cancer but PD-1 is also expressed by other immune cells, including follicular helper CD4 T cells (Tfh) which are involved in germinal centre responses. Little is known, however, about the effects of anti-PD-1 immunotherapy on noncancer immune responses in humans. To investigate this question, we examined the impact of anti-PD-1 immunotherapy on the Tfh-B cell axis responding to unrelated viral antigens. Following influenza vaccination, a subset of adults receiving anti-PD-1 had more robust circulating Tfh responses than adults not receiving immunotherapy. PD-1 pathway blockade resulted in transcriptional signatures of increased cellular proliferation in circulating Tfh and responding B cells compared with controls. These latter observations suggest an underlying change in the Tfh-B cell and germinal centre axis in a subset of immunotherapy patients. Together, these results demonstrate dynamic effects of anti-PD-1 therapy on influenza vaccine responses and highlight analytical vaccination as an approach that may reveal underlying immune predisposition to adverse events.
PMID: 35902637
ISSN: 1529-2916
CID: 5276912

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals

Samanovic, Marie I; Cornelius, Amber R; Gray-Gaillard, Sophie L; Allen, Joseph Richard; Karmacharya, Trishala; Wilson, Jimmy P; Wesley Hyman, Sara; Tuen, Michael; Koralov, Sergei B; Mulligan, Mark J; Sedaghat Herati, Ramin
[Figure: see text].
PMID: 34874183
ISSN: 1946-6242
CID: 5086932

The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response

Oom, Aaron L; Wilson, Kesi K; Yonatan, Miilani; Rettig, Stephanie; Youn, Heekoung Allison; Tuen, Michael; Shah, Yusra; DuMont, Ashley L; Belli, Hayley M; Zucker, Jane R; Rosen, Jennifer B; Herati, Ramin Sedaghat; Samanovic, Marie I; Duerr, Ralf; Kottkamp, Angelica C; Mulligan, Mark J; ,
UNLABELLED:The 2022 global outbreak of clade IIb mpox was the first major outbreak of mpox outside of African nations. To control the outbreak, public health officials began vaccination campaigns using the third-generation orthopoxvirus vaccine modified vaccinia Ankara from Bavarian Nordic (MVA-BN). Prior to this outbreak, the durability of monkeypox virus (MPXV)-specific immunity induced by MVA-BN was poorly understood. In 2022, we launched the New York City Observational Study of Mpox Immunity (NYC OSMI, NCT05654883), a longitudinal study of 171 participants comprising MVA-BN vaccines and mpox convalescent individuals. Peripheral blood sampling was performed at intervals including prior to vaccination, after one dose, and after the second dose. MVA-BN vaccinees with and without a history of smallpox vaccination demonstrated detectable MPXV-specific memory B cells at 1-year post-vaccination. Additionally, MVA-BN increased MPXV neutralizing titers in smallpox vaccine-naïve vaccinees, with a comparable maximum titer reached in naïve and smallpox vaccine-experienced vaccinees. However, neutralizing titers returned to baseline within 5-7 months for naïve individuals, while remaining elevated in those with prior smallpox vaccination. Both naïve and experienced individuals generated robust IgG responses against MPXV H3 and A35, but naïve vaccinees' IgG responses showed lower avidity than experienced vaccinees. These data highlight a low avidity antibody response elicited by MVA-BN that is short-lived in naïve vaccinees. This work supports the need for long-term studies on protection induced by MVA-BN, including the potential need for booster doses as well as the development of next-generation orthopoxvirus vaccines. IMPORTANCE/OBJECTIVE:The ongoing outbreaks of mpox demonstrate the continuing threat of orthopoxviruses to global health. While previous orthopoxvirus vaccines generated lifelong antibody and cellular immunity, we show here that the current mpox vaccine, MVA-BN or JYNNEOS, fails to induce durable antibody immunity in individuals with no prior smallpox vaccination. This raises the important question of whether MVA-BN vaccinees have long-term protection from mpox. Our work highlights the need for further studies into the durability of protection generated by MVA-BN as well as whether subsequent booster doses are necessary to maintain protection.
PMID: 40162783
ISSN: 1098-5514
CID: 5818712

Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells

Zhang, Zhen; Langenbach, Marlene; Sagar, Sagar; Fetsch, Viktor; Stritzker, Jonas; Severa, Elizabeth; Meng, Ke; Winkler, Frances; Rana, Nisha; Zoldan, Katharina; Godbole, Ira; Solis, Sabrina; Weber, Jeffrey S; Rafei-Shamsabadi, David; Lehr, Saskia; Diehl, Rebecca; Venhoff, Ana Cecilia; Voll, Reinhard E; Buettner, Nico; Neumann-Haefelin, Christoph; Boettler, Tobias; Hofmann, Maike; Boerries, Melanie; Meiss, Frank; Zeiser, Robert; Thimme, Robert; Herati, Ramin S; Bengsch, Bertram
The mechanisms underlying the efficacy of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) therapy are incompletely understood. Here, by immune profiling responding PD-1+CD8+ T (TResp) cell populations from patients with advanced melanoma, we identified differential programming of TResp cells in response to combination therapy, from an exhausted toward a more cytotoxic effector program. This effect does not occur with anti-PD-1 monotherapy. Single-cell transcriptome and T cell receptor repertoire analysis was used to identify altered effector programming of expanding PD-1+CD8+ T cell clones with distinct regulon usage, STAT1 and STAT3 utilization and antitumor specificity connected to interleukin (IL)-21 signaling in combination and anti-CTLA-4 monotherapy. Therapeutic efficacy of CTLA-4 blockade was lost in B16F10 melanoma models with either Il21r- deficiency or anti-IL-21 receptor blockade. Together, these results show how IL-21 signaling to TResp is critical for anti-CTLA-4-based checkpoint therapies and highlight major signaling differences to anti-PD-1 monotherapy.
PMID: 39702858
ISSN: 1529-2916
CID: 5764842

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells

Wang, Kevin; Coutifaris, Paulina; Brocks, David; Wang, Guanning; Azar, Tarek; Solis, Sabrina; Nandi, Ajeya; Anderson, Shaneaka; Han, Nicholas; Manne, Sasikanth; Kiner, Evgeny; Sachar, Chirag; Lucas, Minke; George, Sangeeth; Yan, Patrick K; Kier, Melanie W; Laughlin, Amy I; Kothari, Shawn; Giles, Josephine; Mathew, Divij; Ghinnagow, Reem; Alanio, Cecile; Flowers, Ahron; Xu, Wei; Tenney, Daniel J; Xu, Xiaowei; Amaravadi, Ravi K; Karakousis, Giorgos C; Schuchter, Lynn M; Buggert, Marcus; Oldridge, Derek; Minn, Andy J; Blank, Christian; Weber, Jeffrey S; Mitchell, Tara C; Farwell, Michael D; Herati, Ramin S; Huang, Alexander C
Combination checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies has shown promising efficacy in melanoma. However, the underlying mechanism in humans remains unclear. Here, we perform paired single-cell RNA and T cell receptor (TCR) sequencing across time in 36 patients with stage IV melanoma treated with anti-PD-1, anti-CTLA-4, or combination therapy. We develop the algorithm Cyclone to track temporal clonal dynamics and underlying cell states. Checkpoint blockade induces waves of clonal T cell responses that peak at distinct time points. Combination therapy results in greater magnitude of clonal responses at 6 and 9 weeks compared to single-agent therapies, including melanoma-specific CD8+ T cells and exhausted CD8+ T cell (TEX) clones. Focused analyses of TEX identify that anti-CTLA-4 induces robust expansion and proliferation of progenitor TEX, which synergizes with anti-PD-1 to reinvigorate TEX during combination therapy. These next generation immune profiling approaches can guide the selection of drugs, schedule, and dosing for novel combination strategies.
PMCID:11387127
PMID: 39214097
ISSN: 1878-3686
CID: 5689842

Integrative multi-omics profiling in human decedents receiving pig heart xenografts

Schmauch, Eloi; Piening, Brian; Mohebnasab, Maedeh; Xia, Bo; Zhu, Chenchen; Stern, Jeffrey; Zhang, Weimin; Dowdell, Alexa K; Kim, Jacqueline I; Andrijevic, David; Khalil, Karen; Jaffe, Ian S; Loza, Bao-Li; Gragert, Loren; Camellato, Brendan R; Oliveira, Michelli F; O'Brien, Darragh P; Chen, Han M; Weldon, Elaina; Gao, Hui; Gandla, Divya; Chang, Andrew; Bhatt, Riyana; Gao, Sarah; Lin, Xiangping; Reddy, Kriyana P; Kagermazova, Larisa; Habara, Alawi H; Widawsky, Sophie; Liang, Feng-Xia; Sall, Joseph; Loupy, Alexandre; Heguy, Adriana; Taylor, Sarah E B; Zhu, Yinan; Michael, Basil; Jiang, Lihua; Jian, Ruiqi; Chong, Anita S; Fairchild, Robert L; Linna-Kuosmanen, Suvi; Kaikkonen, Minna U; Tatapudi, Vasishta; Lorber, Marc; Ayares, David; Mangiola, Massimo; Narula, Navneet; Moazami, Nader; Pass, Harvey; Herati, Ramin S; Griesemer, Adam; Kellis, Manolis; Snyder, Michael P; Montgomery, Robert A; Boeke, Jef D; Keating, Brendan J
In a previous study, heart xenografts from 10-gene-edited pigs transplanted into two human decedents did not show evidence of acute-onset cellular- or antibody-mediated rejection. Here, to better understand the detailed molecular landscape following xenotransplantation, we carried out bulk and single-cell transcriptomics, lipidomics, proteomics and metabolomics on blood samples obtained from the transplanted decedents every 6 h, as well as histological and transcriptomic tissue profiling. We observed substantial early immune responses in peripheral blood mononuclear cells and xenograft tissue obtained from decedent 1 (male), associated with downstream T cell and natural killer cell activity. Longitudinal analyses indicated the presence of ischemia reperfusion injury, exacerbated by inadequate immunosuppression of T cells, consistent with previous findings of perioperative cardiac xenograft dysfunction in pig-to-nonhuman primate studies. Moreover, at 42 h after transplantation, substantial alterations in cellular metabolism and liver-damage pathways occurred, correlating with profound organ-wide physiological dysfunction. By contrast, relatively minor changes in RNA, protein, lipid and metabolism profiles were observed in decedent 2 (female) as compared to decedent 1. Overall, these multi-omics analyses delineate distinct responses to cardiac xenotransplantation in the two human decedents and reveal new insights into early molecular and immune responses after xenotransplantation. These findings may aid in the development of targeted therapeutic approaches to limit ischemia reperfusion injury-related phenotypes and improve outcomes.
PMID: 38760586
ISSN: 1546-170x
CID: 5654102

mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection

Ivanova, Ellie N; Shwetar, Jasmine; Devlin, Joseph C; Buus, Terkild B; Gray-Gaillard, Sophie; Koide, Akiko; Cornelius, Amber; Samanovic, Marie I; Herrera, Alberto; Mimitou, Eleni P; Zhang, Chenzhen; Karmacharya, Trishala; Desvignes, Ludovic; Ødum, Niels; Smibert, Peter; Ulrich, Robert J; Mulligan, Mark J; Koide, Shohei; Ruggles, Kelly V; Herati, Ramin S; Koralov, Sergei B
SARS-CoV-2 infection and vaccination elicit potent immune responses. Our study presents a comprehensive multimodal single-cell analysis of blood from COVID-19 patients and healthy volunteers receiving the SARS-CoV-2 vaccine and booster. We profiled immune responses via transcriptional analysis and lymphocyte repertoire reconstruction. COVID-19 patients displayed an enhanced interferon signature and cytotoxic gene upregulation, absent in vaccine recipients. B and T cell repertoire analysis revealed clonal expansion among effector cells in COVID-19 patients and memory cells in vaccine recipients. Furthermore, while clonal αβ T cell responses were observed in both COVID-19 patients and vaccine recipients, expansion of clonal γδ T cells was found only in infected individuals. Our dataset enables side-by-side comparison of immune responses to infection versus vaccination, including clonal B and T cell responses. Our comparative analysis shows that vaccination induces a robust, durable clonal B and T cell responses, without the severe inflammation associated with infection.
PMID: 38213787
ISSN: 2589-0042
CID: 5755392

Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection

Zhang, Bingjie; Upadhyay, Rabi; Hao, Yuhan; Samanovic, Marie I; Herati, Ramin S; Blair, John D; Axelrad, Jordan; Mulligan, Mark J; Littman, Dan R; Satija, Rahul
The immune response to SARS-CoV-2 antigen after infection or vaccination is defined by the durable production of antibodies and T cells. Population-based monitoring typically focuses on antibody titer, but there is a need for improved characterization and quantification of T cell responses. Here, we used multimodal sequencing technologies to perform a longitudinal analysis of circulating human leukocytes collected before and after immunization with the mRNA vaccine BNT162b2. Our data indicated distinct subpopulations of CD8+ T cells, which reliably appeared 28 days after prime vaccination. Using a suite of cross-modality integration tools, we defined their transcriptome, accessible chromatin landscape and immunophenotype, and we identified unique biomarkers within each modality. We further showed that this vaccine-induced population was SARS-CoV-2 antigen-specific and capable of rapid clonal expansion. Moreover, we identified these CD8+ T cell populations in scRNA-seq datasets from COVID-19 patients and found that their relative frequency and differentiation outcomes were predictive of subsequent clinical outcomes.
PMID: 37735591
ISSN: 1529-2916
CID: 5606242

Immune response, phenotyping and molecular graft surveillance in kidney transplant recipients following severe acute respiratory syndrome coronavirus 2 vaccination

Ali, Nicole M; Herati, Ramin S; Mehta, Sapna A; Leonard, Jeanette; Miles, Jake; Lonze, Bonnie E; DiMaggio, Charles; Tatapudi, Vasishta S; Stewart, Zoe A; Alnazari, Nasser; Neumann, Henry J; Thomas, Jeffrey; Cartiera, Katarzyna; Weldon, Elaina; Michael, Jennifer; Hickson, Christopher; Whiteson, Harris; Khalil, Karen; Stern, Jeffrey M; Allen, Joseph R; Tuen, Michael; Gray-Gaillard, Sophie L; Solis, Sabrina M; Samanovic, Marie I; Mulligan, Mark J; Montgomery, Robert A
BACKGROUND:Understanding immunogenicity and alloimmune risk following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in kidney transplant recipients is imperative to understanding the correlates of protection and to inform clinical guidelines. METHODS:We studied 50 kidney transplant recipients following SARS-CoV-2 vaccination and quantified their anti-spike protein antibody, donor-derived cell-free DNA (dd-cfDNA), gene expression profiling (GEP), and alloantibody formation. RESULTS:Participants were stratified using nucleocapsid testing as either SARS-CoV-2-naïve or experienced prior to vaccination. One of 34 (3%) SARS-CoV-2 naïve participants developed anti-spike protein antibodies. In contrast, the odds ratio for the association of a prior history of SARS-CoV-2 infection with vaccine response was 18.3 (95% confidence interval 3.2, 105.0, p < 0.01). Pre- and post-vaccination levels did not change for median dd-cfDNA (0.23% vs. 0.21% respectively, p = 0.13), GEP scores (9.85 vs. 10.4 respectively, p = 0.45), calculated panel reactive antibody, de-novo donor specific antibody status, or estimated glomerular filtration rate. CONCLUSIONS:SARS-CoV-2 vaccines do not appear to trigger alloimmunity in kidney transplant recipients. The degree of vaccine immunogenicity was associated most strongly with a prior history of SARS-CoV-2 infection.
PMID: 37707287
ISSN: 1399-3062
CID: 5593762